The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Open accessAbstract
Purpose: To evaluate the efficacy and safety of clofarabine, a novel deoxyadenosine analog, in pediatric patients with refractory or relapsed acute lymphoblastic leukemia (ALL). Patients and Methods: In a phase II, open-label, multicenter study, 61 pediatric patients with refractory or relapsed ALL received clofarabine 52 mg/m 2 intravenously over 2 hours daily for 5 days, every 2 to 6 weeks. The median age was 12 years (range, 1 to 20 years), and the median number of prior regimens was three (range, two to six regimens). Results: The response rate was 30%, consisting of seven complete remissions (CR), five CRs without platelet recovery (CRp), and six partial remissions. Remissions were durable enough to allow patients to proceed to hematopoietic stem-cell transplantation (HSCT) after clofarabine. Median CR duration in patients who did not receive HSCT was 6 weeks, with four patients maintaining CR or CRp for 8 weeks or more (8+, 12, 37+, and 48 weeks) on clofarabine therapy alone. The most common adverse events of grade ≥ 3 were febrile neutropenia, anorexia, hypotension, and nausea. Conclusion: Clofarabine is active as a single agent in pediatric patients with multiple relapsed or refractory ALL. The toxicity profile is as expected in this heavily pretreated patient population. Studies exploring rational combinations of clofarabine with other agents are ongoing in an effort to maximize clinical benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Cheson, B. D., Cassileth, P. A., Head, D. R., Schiffer, C. A., Bennett, J. M., Bloomfield, C. D., Brunning, R., Gale, R. P., Grever, M. R., & Keating, M. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.813 · Cited by 770
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Pui, C.-H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322407 · Cited by 379
Berg, S. L., Blaney, S. M., Devidas, M., Lampkin, T. A., Murgo, A., Bernstein, M., Billett, A., Kurtzberg, J., Reaman, G., Gaynon, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.426 · Cited by 318
Self-citationKantarjian, H., Gandhi, V., Cortes, J., Verstovsek, S., Du, M., Garcia-Manero, G., Giles, F., Faderl, S., O'Brien, S., Jeha, S., et al. (2003) · Blood · doi:10.1182/blood-2003-03-0925 · Cited by 314
Self-citationStevens, R. F., Hann, I. M., Wheatley, K., Gray, R. G., & Party, O. B. O. T. M. C. L. W. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00677.x · Cited by 309
Cancer chemotherapy and biological response modifiers annual
Pinedo, H. M., Longo, D. L., & Chabner, B. A. (1987) · Elsevier eBooks · Cited by 269
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia
Jeha, S., Gandhi, V., Chan, K. W., McDonald, L., Ramirez, I., Madden, R., Rytting, M., Brandt, M., Keating, M., Plunkett, W., et al. (2004) · Blood · doi:10.1182/blood-2003-06-2122 · Cited by 256
Self-citationRegulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives
Hirschfeld, S., Ho, P. T. C., Smith, M., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.138 · Cited by 229
Cited by
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Gökbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H.-A., Hüttmann, A., Kobbe, G., Kreuzer, K.-A., Leimer, L., Reichle, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399287 · Cited by 472
A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.06.007 · Cited by 368
Metadata
- Authors
- Jeha, S., Gaynon, P. S., Razzouk, B. I., Franklin, J., Kadota, R., Shen, V., Luchtman-Jones, L., Rytting, M., Bomgaars, L. R., Rheingold, S., Ritchey, K., Albano, E., Arceci, R. J., Goldman, S., Griffin, T., Altman, A., Gordon, B., Steinherz, L., Weitman, S., & Steinherz, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-04-20
- Volume
- 24
- Issue
- 12
- Pages
- 1917-1923
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160881482
- Cited by
- 308
- References
- 25
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia. https://app.cochat.ai/papers/10.1200/jco.2005.03.8554
- The paper
- Jeha, S., Gaynon, P. S., Razzouk, B. I., Franklin, J., Kadota, R., Shen, V., Luchtman-Jones, L., Rytting, M., Bomgaars, L. R., Rheingold, S., Ritchey, K., Albano, E., Arceci, R. J., Goldman, S., Griffin, T., Altman, A., Gordon, B., Steinherz, L., Weitman, S., & Steinherz, P. (2006). Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.03.8554
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.